A Phase i study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2262-2267

  Chen, E X ^a   Hotte, S ^b   Hirte, H ^b   Siu, L L ^a   Lyons, J ^c   Squires, M ^c   Lovell, S ^a   Turner, S ^b   McIntosh, L ^d   Seymour, L ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d Queen's Cancer Research Institute   (Canada)

Author keywords

AT7519; cyclin dependent kinase; pharmacokinetics; phase I study

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AT 7519; BIOLOGICAL MARKER; CREATININE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG; 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENZYME ACTIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN BIOPSY; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY ASSAY; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84927570857     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.565     Document Type: Article

References (20)

1. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7: 353-370.
2. Canavese M, Santo L, Raje N (2012) Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 13(7): 451-457.
3. Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin 137(10): 1409-1418.
4. Finn RS, Dieras V, Gelmon KA, Harbeck N, Jones SE, Koehler M, Martin M, Rugo HS, Im S-A, Toi M, Gauthier ER, Huang X, Randolph S, Slamon DJ (2013) A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(\+), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. J Clin Oncol. Meeting Abstracts 31(15-suppl): TPS652.
5. Galons H, Oumata N, Gloulou O, Meijer L (2013) Cyclin-dependent kinase inhibitors closer to market launch? Expert Opin Ther Pat 23(8): 945-963.
6. Johnson N, Shapiro GI (2010) Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Tar 14(11): 1199-1212.
7. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H, Noguchi S (2008) Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 19(1): 68-72.
8. Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott Rene G, Schäfer M, Fajmann S, Schlederer M, Schiefer A-I, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green Anthony R, Moriggl R, Busslinger M, Malumbres M, Sexl V (2013) A kinase-independent function of cdk6 links the cell cycle to tumor angiogenesis. Cancer Cell 24(2): 167-181.
9. Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM. National Cancer Institute of Canada Clinical Trials G (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(9): 1740-1745.
10. Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, Yamamoto K (1999) The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clinl Cancer Res 5(12): 4152-4157.
11. Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H (2011) A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol 22(9): 2137-2143.
12. Malumbres M (2012) Cell cycle-based therapies move forward. Cancer Cell 22(4): 419-420.
13. Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Drexler HG, Zettl A, Rosenwald A, MacLeod RAF (2007) Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 22(2): 387-392.
14. Poomsawat S, Buajeeb W, Khovidhunkit SO, Punyasingh J (2010) Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. J Oral Pathol Med 39(10): 793-799.
15. Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N (2010) AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29(16): 2325-2336.
16. Squires MS, Cooke L, Lock V, Qi W, Lewis EJ, Thompson NT, Lyons JF, Mahadevan D (2010) AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 9(4): 920-928.
17. Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, Lyons JF, Thompson NT (2009) Biological characterization of AT7519, a smallmolecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 8(2): 324-332.
18. Therasse P, Eisenhauer EA, Buyse M (2006) Update in methodology and conduct of cancer clinical trials. Eur J Cancer 42(10): 1322-1330.
19. Vaughn DJ, Gallagher M, Lal P, Rosen MA, Hwang W-T, Einhorn LH, O'Dwyer PJ (2012) Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors. J Clin Oncol (Meeting Abstracts) 30(15-suppl): 4596.
20. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, Saxty G, Seavers LC, Smith DM, Squires MS, Trewartha G, Walker MT, Woolford AJ (2008) Identification of N-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1Hpyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 51(16): 4986-4999.